脐血CD_3AK细胞治疗难治性恶性淋巴瘤的临床研究  

CLINICAL EFFECTS OF CD_3 AK CELLS DERIVED FROM CORD BLOOD ON REFRACTORY LYMPHOMA

作　　者：苏毅[1] 赵碧[1] 赵越华[1] 邵文军[1] 郑华金[1] 

机构地区：[1]成都军区总医院血液科,成都610083

出　　处：《西南国防医药》2001年第2期91-92,共2页Medical Journal of National Defending Forces in Southwest China

摘　　要：目的:探讨脐血CD3AK细胞对难治性恶性淋巴瘤的治疗作用。方法:分离脐血单个核细胞,采用Anti—CD3McAb和rIl-2以及PHA诱生CD3AK细胞。运用MTT法测定CD3AK细胞的杀瘤活性,并采用静脉输注和瘤体内注射治疗难治性恶性淋巴瘤15例。结果:脐血单个核细胞诱生的CD3AK细胞在体外对K562和Raji细胞有明显杀伤作用,治疗15例难治性恶性淋巴瘤,完全缓解4例,部分缓解2例,有效率40％。结论:脐血CD3AK细胞对难治性淋巴瘤具有较好疗效。Objective To study the clinical effects of CD3 AK cells on refractory lymphoma. Method CD3 AK cells were prepared with monocytes separated from cord blood and then induced by anti - CD3 McAb, rIL - 2 and PHA. The activity of CD3 AK cells was measured with MTT method. Result K562 and Raji cell were killed significantly by CD3 AK cells in vitro. 4 of 15 patients treated with CD3 AK cells alleviated completely and 2 alleviated partially. The total effective rate was 40% . Conclusion: CD3 AK cells derived from cord blood are hopeful to the treatment of refractory lymphoma.

关 键 词：CD3AK细胞 脐血 恶性淋巴瘤 治疗 

分 类 号：R733.405[医药卫生—肿瘤]